Case Study: Data Analytics Enables Program Improvements and Faster Access to Therapy
White Paper: Beyond the Promise of Artificial Intelligence in Electronic Benefit Verification
The future of eBV is here. How manufacturers can use AI to help patients start life-changing therapies faster than ever.
Scaling Up for Annual Reverification
Executive Q&A: How to make the annual benefits reverification process as smooth as possible for patients and key stakeholders.
How to Launch a Patient Support Program
Executive Q&A: best practices for a patient support program launch.
Coordinated Care: The Value of Patient and Provider Satisfaction within Health System Specialty Pharmacies
Download this new white paper from IHOC - Coordinated Care: The Value of Patient and Provider Satisfaction within Health System Specialty Pharmacies - to learn the key insights about the role HSSPs play in improving the patient experience and why patient and provider satisfaction are important data points for both payers and manufacturers to consider when deciding to include HSSPs in their networks.
Moving Medicare Coverage
Executive Q&A: How shifting coverage for some drugs from Medicare Part B to Part D could impact access and affordability for patients.
Preparing Patients for Open Enrollment
Open enrollment for Health Insurance Marketplace plans is here. Do PAP patients know their coverage options?
Rethink: Channel Strategy for Oral Oncolytics
How manufacturers can benefit from provider-led care coordination to improve patient outcomes.
Commercially Available Unit Dose Products: Enhancing Access to Treatments and Promoting Pharmacy Efficiency
While suppliers are making fewer pre-packaged unit dose treatments available, health system pharmacies still have options for acquiring them. Learn which is best.
How Product Commercialization Impacts Patients
How do channel strategy decisions impact providers and patients—and how can you ensure a patient-centric commercialization strategy? Our strategic global sourcing experts share insights on how customers respond to channel strategy decisions.
A New Approach to Channel Strategy for Oncology Therapies
How is manufacturer thinking around channel strategy changing for oral oncolytics?
Full-line vs. Specialty Distribution
What manufacturers need to know about how distribution impacts access.
Upping the Game
How drug manufacturers, health systems and payers can collaborate more closely in the new world of patient-centered care.
How do manufacturers' distribution decisions ultimately impact patients? What long- and short-term disruption do direct models present? AmerisourceBergen experts offer perspective on the unintended consequences of channel strategy decisions.
Leadership in Specialty
Our strategic global sourcing experts share how AmerisourceBergen's leadership in specialty distribution influences the way we partner with manufacturers.
An Inside Look at the Customer Experience
Our experts share what customers wish manufacturers knew about product access.
The Downstream Impact of Channel Strategy Decisions
What manufacturers need to know about the customer experience.
Affordability and Access Will Drive Biosimilar Success
U.S. biosimilars are coming, just as they’ve arrived and prospered in the Europe. By ensuring positive patient experiences, specialty pharmacies will help usher in a sustainable wave of biosimilar products.
How Wholesalers Have Evolved in Recent Years
How pharmaceutical wholesalers have evolved in recent years.
Commercializing Cell and Gene Therapies
Learn what it takes to design an effective commercialization strategy and execute an integrated solution when the patient is in the supply chain.
Practical Data in an Insights-driven World
How should manufacturers be using distribution data to uncover insights and manage access?
Patient-Centric Product Commercialization: Part Three
Designing support programs that are truly patient-centric and overcoming obstacles along the way.
Patient-Centric Product Commercialization: Part Two
Mapping the patient journey and building support programs that address the three biggest hurdles patients face.
Patient-Centric Product Commercialization: Part One
How can manufacturers turn patient-centricity from buzzword into reality?